Skip to main content
SpringerLink
Log in

Gewichtsveränderungen unter Neuroleptika: Epidemiologie, Regulationsmechanismen und klinische Aspekte

  • Conference paper
Leponex

Zusammenfassung

Gewichtszunahmen unter neuroleptischer Therapie sind ein bekanntes klinisches Phänomen. Vor dem Hintergrund einer so schwerwiegenden Grunderkrankung wie einer schizophrenen Psychose werden die Gewichtsveränderungen allerdings anfänglich kaum bemerkt oder als eher „harmlose“ Nebenwirkung in Kauf genommen Nach einigen Monaten jedoch kann die Gewichtszunahme 20 Kilogramm und mehr betragen, und der Patient trägt neben seiner Grunderkrankung die Last einer pharmakologisch induzierten Adipositas.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ (1999a) The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 60: 215–220

    Article  PubMed  CAS  Google Scholar 

  • Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999b) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686–1696

    PubMed  CAS  Google Scholar 

  • Amidsen A (1964) Drug-produced obesity–Experiences with chlorpromazine, perphenazine and clopenthixol. Dan Med Bull 11: 182–189

    Google Scholar 

  • Anghelescu I, Szegedi A, Schlegel S, Weigmann H, Hiemke C, Wetzel H (1998) Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial. Eur Neuropsychopharmacol 8: 315–320

    Article  PubMed  CAS  Google Scholar 

  • Aquila R, Emanuel M (1999) Weight gain and antipsychotic medications. J Clin Psychiatry 60: 336

    Article  PubMed  CAS  Google Scholar 

  • Atkinson RL, Stern JS (1998) Weight cycling. In: Bray GA, Bouchard C, James WPT (eds) Handbook of obesity. Marcel Dekker, New York, pp 791–804

    Google Scholar 

  • Baptista T, Parada M, Hernandez L (1987) Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav 27: 399–405

    Article  PubMed  CAS  Google Scholar 

  • Baptista T, Lopez ME, Teneud L et al. (1997a) Amantadine in the treatment of neurolepticinduced obesity in rats: behavioral, endocrine and neurochemical correlates. Pharmacopsychiatry 30: 43–54

    Article  PubMed  CAS  Google Scholar 

  • Baptista T, de Baptista EA, Hernandez L, Altemus M, Weiss SR (1997b) Tamoxifen prevents sulpiride-induced weight gain in female rats. Pharmacol Biochem Behav 57: 215–222

    Article  CAS  Google Scholar 

  • Baptista T (1999) Body weight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psychiatr Scand 100: 3–16

    Article  PubMed  CAS  Google Scholar 

  • Baptista T, Lacruz A, Acosta A, Colasante C, de Quijada M, de Mendoza S, Mendoza JM, Hernandez L (2000) Naltrexone does not prevent the weight gain and hyperphagia induced by the antipsychotic drug sulpiride in rats. Appetite 34: 77–86

    Article  PubMed  CAS  Google Scholar 

  • Baumann P (1996) Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31: 444–469

    Article  PubMed  CAS  Google Scholar 

  • Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN (1997) Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 7: 125–137

    Article  PubMed  CAS  Google Scholar 

  • Bernstein JG (1988) Psychotic drug induced weight gain: mechanismus and managment. Clin Neuropharmacol 11: 194–206

    Google Scholar 

  • Blackburn GL (2000) Weight gain and antipsychotic medication. J Clin Psychiatry 61 (Suppl 8): 36–41

    PubMed  Google Scholar 

  • Bleuler E (1930) Textbook of Psychiatry. Mac-Millan, New York

    Google Scholar 

  • Bray GA (1989) Classification and evaluation of the obesities. Med Clin N Am 73: 161–184

    PubMed  CAS  Google Scholar 

  • Brömel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg JC, Hebebrand J (1998) Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 3: 76–80

    Article  PubMed  Google Scholar 

  • Brömel T, Hinney A, Schulz E, Theisen F, Remschmidt H, Krieg J-C, Hebebrand J (1999) Das Körpergewicht im Rahmen der Schizophrenie unter besonderer Berücksichtigung der Clozapin-induzierten Gewichtszunahme und dem damit einhergehenden Anstieg der Leptinsekretion. In: Naber D, Müller-Spahn F (Hrsg) Leponex. Pharmakologie und Klinik eines atypischen Neuroleptikums. Springer, Berlin, Heidelberg, S 63–78

    Google Scholar 

  • Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13: 177–213

    Article  PubMed  CAS  Google Scholar 

  • Cabanac M, Duclaux R, Spector NH (1971) Sensory feedback in regulation of body weight: is there a ponderostat? Nature 229: 125–127

    Article  PubMed  CAS  Google Scholar 

  • Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP (1991) Fluoxetine’s effect on weight loss in obese subjects. Am J Clin Nutr 54: 321–325

    PubMed  CAS  Google Scholar 

  • American Psychiatric Association (1994) DSM-IV. Diagnostic and statistical manual of mental disorders, 4tß, edn. American Psychiatric Association, Washington, DC

    Google Scholar 

  • Dursun SM, Devarajan S (2000) Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 45: 198

    PubMed  CAS  Google Scholar 

  • Dursun SM, Szemis A, Andrews H, Reveley MA (1999) The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J Psychiatry Neurosci 24: 453–455

    PubMed  CAS  Google Scholar 

  • Fertig MK, Brooks VG, Shelton PS, English CW (1998) Hyperglycemia associated with olanzapine. J Clin Psychiatry 59: 687–689

    Article  PubMed  CAS  Google Scholar 

  • Frankenburg FR, Zanarini MC, Kando J, Centorrino F (1998) Clozapine and body mass change. Biol Psychiatry 43: 520–524

    Article  PubMed  CAS  Google Scholar 

  • Franz M, Lis S, Pluddemann K, Gallhofer B (1997) Conventional versus atypical neurolep- tics: subjective quality of life in schizophrenic patients. Br J Psychiatry 170: 422–425

    Article  PubMed  CAS  Google Scholar 

  • Gaebel W, Klimke A, Klieser E (1994) Kombination von Clozapin mit anderen Psychopharmaka. In: Naher D, Müller-Spahn F (Hrsg) Clozapin. Pharmakologie and Klinik eines atypischen Neuroleptikums. Neuere Aspekte der klinischen Praxis. Springer, Berlin Heidelberg, S 53

    Google Scholar 

  • Garrow JS, Webster J (1985) Quetelet’s index (W/H2) as a measure of fatness. Int J Obes 9: 147–153

    PubMed  CAS  Google Scholar 

  • Gatta B, Rigalleau V, Gin H (1999) Diabetic ketoacidosis with olanzapine treatment. Diabetes Care 22: 1002–1003

    Article  PubMed  CAS  Google Scholar 

  • Gaulin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL (1999) Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 156: 1270–1272

    PubMed  CAS  Google Scholar 

  • Ghaeli P, Dufresne RL (1999) Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacotherapy 19: 1099–1101

    Article  PubMed  CAS  Google Scholar 

  • Goldstein DJ (1992) Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 16: 397–415

    PubMed  CAS  Google Scholar 

  • Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, Sachs G, Stern TA (1999) New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40: 438–443

    PubMed  CAS  Google Scholar 

  • Gopalaswamy AK, Morgan R (1985) Too many chronic mentally disabled patients are too fat. Acta Psychiatr Scand 72: 254–258

    Article  PubMed  CAS  Google Scholar 

  • Gordon A, Price LH (1999) Mood stabilization and weight loss with topiramate. Am J Psychiatry 156: 968–969

    PubMed  CAS  Google Scholar 

  • Gordon HL, Groth C (1964) Weight change during and after hospital treatment. Arch Gen Psychiatry 10: 115–119

    Google Scholar 

  • Gortmaker SL, Must A, Perrin JM, Sobol AM, Dietz WH (1993) Social and economic consequences of overweight in adolescence and young adulthood. N Engl J Med 329: 1008–1012

    Article  PubMed  CAS  Google Scholar 

  • Green B (1999) Focus on olanzapine. Curr Med Res Opin 15: 79–85

    Article  PubMed  CAS  Google Scholar 

  • Grundy SM (1998) Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrom. Am J Cardiol 81: 18B - 25B

    Article  PubMed  CAS  Google Scholar 

  • Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R (1998) Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 59: 294–299

    Article  PubMed  CAS  Google Scholar 

  • Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P (1998) A comparison of sibutramine and dexfenfluramine in the treatment of obesity. Obes Res 6: 285–291

    PubMed  CAS  Google Scholar 

  • Hebebrand J, Heseker H, Himmelmann W, Schäfer H, Remschmidt (1994) Altersperzentilen für den Body-Mass-Index aus Daten der Nationalen Verzehrstudie eischließlich einer Übersicht zu relevanten Einflußfaktoren. Akt Ernähr Med 19: 259–265

    Google Scholar 

  • Heiman ML, Ahima RS, Craft LS, Schoner B, Stephens TW, Flier JS (1997) Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress. Endocrinology 138: 3859–3863

    Article  PubMed  CAS  Google Scholar 

  • Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 157: 975–981

    Article  PubMed  CAS  Google Scholar 

  • Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmächer T (2000) Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology 149: 163–169

    Article  PubMed  CAS  Google Scholar 

  • Horrigan JP, Sikich L (1998) Diet and the atypical neuroleptics. J Am Acad Child Adolesc Psychiatry 37: 1126–1127

    Article  PubMed  CAS  Google Scholar 

  • Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I (1993) Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 88: 395–402

    Article  PubMed  CAS  Google Scholar 

  • Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW (1995) Weight gain induced by clozapine. Eur Neuropsychopharmacol 5: 437–440

    PubMed  CAS  Google Scholar 

  • Jalenques I, Tauvron I, Albuisson E, Audy V, Fleury-Duhamel N, Coudert A-J (1996) Weightgain as a predictor of long term clozapine efficacy. Clin Drug Invest 12: 16–25

    Article  CAS  Google Scholar 

  • Jones MW (1998) Topiramate–safety and tolerability. Can J Neurol Sci 25: S13–15

    PubMed  CAS  Google Scholar 

  • Kamran A, Doraiswamy PM, Jane JL, Hammett EB, Dunn L (1994) Severe hyperglycemia associated with high doses of clozapine. Am J Psychiatry 151: 1395

    PubMed  CAS  Google Scholar 

  • Ketter TA, Post RM, Theodore WH (1999) Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 53 (Suppl 2): 53–67

    Google Scholar 

  • Khan A, Faught E, Gilliam F, Kuzniecky R (1999) Acute psychotic symptoms induced by topiramate. Seizure 8: 235–237

    Article  PubMed  CAS  Google Scholar 

  • Kolaczynski JW, Ohannesian JP, Considine RV, Marco CC, Caro JF (1996) Response of leptin to short-term and prolonged overfeeding in humans. J Clin Endocrinol Metabol 81: 4162–4165

    Article  CAS  Google Scholar 

  • Kraepelin E (1893) Psychiatrie–Ein kurzes Lehrbuch für Studirende and Aerzte. 4. Auflage. Verlag von Ambr. Abel, Leipzig, S 154–155

    Google Scholar 

  • Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, Pollmächer T (1999) Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 156: 312–314

    PubMed  CAS  Google Scholar 

  • Krypsin-Exner W (1947) Beiträge zum Verlauf des Körpergewichtes bei Psychosen. Wiener Klin Wschr 59: 531–534

    Google Scholar 

  • Lamberti JS, Bellnier T, Schwarzkopf SB (1992) Weight gain among schizophrenic patients treated with clozapine. Am J Psychiarty 149: 689–690

    CAS  Google Scholar 

  • Lawson WB, Karson CN (1994) Clinical correlates of body weight changes in schizophrenia. J Neuropsychiatry Clin Neurosci 6: 187–188

    PubMed  CAS  Google Scholar 

  • Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M (1992) Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 149: 68–72

    PubMed  CAS  Google Scholar 

  • Lindenmayer JP, Patel R (1999) Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry 156: 1471

    PubMed  CAS  Google Scholar 

  • Luheshi GN, Gardner JD, Rushforth DA, Loudon AS, Rothwell NJ (1999) Leptin actions on food intake and body temperature are mediated by IL-1. Proc Natl Acad Sci USA 96: 7047–7052

    Article  PubMed  CAS  Google Scholar 

  • Luque CA, Rey JA (1999) Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 33: 968–978

    Article  PubMed  CAS  Google Scholar 

  • Madej T, Boguski MS, Bryant SH (1995) Threading analysis suggests that the obese gene product may be a helical cytokine. FEBS Letters 373: 13–18

    Article  PubMed  CAS  Google Scholar 

  • Marcotte D (1998) Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord 50: 245–251

    Article  PubMed  CAS  Google Scholar 

  • Masand PS (1999a) Weight gain and antipsychotic medications. J Clin Psychiatry JCP Visuals

    Google Scholar 

  • Masand PS (1999b) Dr. Masand replies. J Clin Psychiatry 60: 336–337

    Article  Google Scholar 

  • Melkersson KI, Hulting AL, Brismar KE (1999) Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 60: 783–791

    Article  PubMed  CAS  Google Scholar 

  • Naber D (1995) A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 10 (Suppl 3): 133–138

    Article  PubMed  Google Scholar 

  • Newman SC, Bland RC (1991) Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 36: 239–245

    PubMed  CAS  Google Scholar 

  • Nisbett RE (1972) Hunger, obesity, and the ventromedial hypothalamus. Psychol Rev 79: 433–453

    Article  PubMed  CAS  Google Scholar 

  • Ober SK, Hudak R, Rusterholtz A (1999) Hyperglycemia and olanzapine. Am J Psychiatry 156: 970

    PubMed  CAS  Google Scholar 

  • Osser DN, Najarian DM, Dufresne RL (1999) Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 60: 767–770

    Article  PubMed  CAS  Google Scholar 

  • Pijl H, Koppeschaar HP, Willekens FL, Op de Kamp I, Veldhuis HD, Meinders AE (1991) Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obes 15: 237–242

    PubMed  CAS  Google Scholar 

  • Pollmächer T, Hinze-Selch D, Mullington J (1996) Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharm 16: 403–409

    Article  Google Scholar 

  • Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE (1997) Clozapine and associated diabetes mellitus. J Clin Psychiatry 58: 108–111

    Article  PubMed  CAS  Google Scholar 

  • Rietschel M, Naber D, Oberländer H, Holzbach R, Fimmers R, Eggermann K, Möller HJ, Propping P, Nöthen MM (1996) Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 15: 491–496

    Article  PubMed  CAS  Google Scholar 

  • Rietschel M, Naber D, Fimmers R, Möller HJ, Propping P, Nöthen M (1997) Efficacy and side-effects of clozapine not associated with variation in the 5-HT2c receptor. NeuroReport 8: 1999–2003

    Article  PubMed  CAS  Google Scholar 

  • Robinson RG, McHugh PR, Folstein MF (1975) Measurement of appetite disturbances in psychiatric disorders. J Psychiatr Res 12: 59–68

    Article  PubMed  CAS  Google Scholar 

  • Rockwell WJK, Ellinwood EH, Troder DW (1983) Psychtropic drugs promoting weight gain: health risks and treatment implications. South Med J 76: 1407–1412

    Article  PubMed  CAS  Google Scholar 

  • Sargent PA, Sharpley AL, Williams C, Goodall EM, Cowen PJ (1997) 5-HT2c receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 133: 309–312

    Article  PubMed  CAS  Google Scholar 

  • Schulz E, Remschmidt H, Martin M (1994) Clozapin in der Kinder-and Jugendpsychiatrie. In: Naber D, Müller-Spahn F (Hrsg) Clozapin. Pharmakologie and Klinik eines atypischen Neuroleptikums. Neuere Aspekte der klinischen Praxis. Springer, Berlin Heidelberg, S 23–37

    Google Scholar 

  • Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C (1999) Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry 156: 1471–1472

    PubMed  CAS  Google Scholar 

  • Singh MM, DeDios LV, Kline NS (1970) Weight as a correlate of clinical response to psycho-tropic drugs. Psychosomatics 11: 562–570

    PubMed  CAS  Google Scholar 

  • Sletten IW, Gershon S (1966) The effect of chlorpromazine on water and electrolyte balance. J Nery Ment Dis 142: 25–31

    Article  CAS  Google Scholar 

  • Spivak B, Lamschtein C, Talmon Y, Guy N, Mester R, Feinberg I, Kotler M, Weizman A (1999) The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol 22: 98–101

    Article  PubMed  CAS  Google Scholar 

  • Stahl SM (1999) Neuropharmacology of obesity: my receptors made me eat it. J Clin Psychiatry 59: 447–448

    Article  Google Scholar 

  • Stanton JM (1995) Weight gain associated with neuroleptic medication: a review. Schizophr Bull 21: 463–472

    PubMed  CAS  Google Scholar 

  • Stedman T, Welham J (1993) The distribution of adipose tissue in female in-patients receiving psychotropic drugs. Br J Psychiatry 162: 249–250

    Article  PubMed  CAS  Google Scholar 

  • Stinson JC, Murphy CM, Andrews JF, Tomkin GH (1992) An assessment of the thermogenic effects of fluoxetine in obese subjects. Int J Obes Relat Metab Disord 16: 391–395

    PubMed  CAS  Google Scholar 

  • Svacina S, Sonka J, Marek J (1998) Dexfenfluramine in psychotic patients. Int J Eat Disord 24: 335–338

    Article  PubMed  CAS  Google Scholar 

  • Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, Hartter S, Hiemke C, Wetzel H (1999) Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32: 148–153

    Article  PubMed  CAS  Google Scholar 

  • Tartaglia LA, Dembski M, Weng X et al. (1995) Identification and expression cloning of a leptin receptor, OB-R. Cell 83: 1263–1271

    Google Scholar 

  • Theisen FM, Cichon S, Linden A, Martin M, Remschmidt H, Hebebrand J. Clozapine treatment results in similar weight gain in a pair of monozygotic twins. Am J Psychiatry, im Druck

    Google Scholar 

  • Umbricht DS, Pollack S, Kane JM (1994) Clozapine and weight gain. J Clin Psychiatry 55 (Suppl B): 157–160

    PubMed  Google Scholar 

  • Vojvoda D, Grimmell K, Sernyak M, Mazure CM (1996) Monozygotic twins concordant for response to clozapine. Lancet 347 (8993): 61

    Article  PubMed  CAS  Google Scholar 

  • Wannamethee SG, Shaper AG, Durrington PN, Perry IJ (1998) Hypertension, serum insulin, obesity and the metabolic syndrome. J Hum Hypertens 12: 735–741

    Article  PubMed  CAS  Google Scholar 

  • Weigle DS (1994) Appetite and regulation of body coposition. The FASEB Journal 8: 302–310

    PubMed  CAS  Google Scholar 

  • Wetterling T, Müssigbrodt HE (1999) Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 19: 316–321

    Article  PubMed  CAS  Google Scholar 

  • Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Harter S, Hiemke C (1998) Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 18: 2–9

    Article  PubMed  CAS  Google Scholar 

  • Wiebe EJ (1993) Weight gain with clozapine treatment. Can J Psychiatry 38: 70

    PubMed  CAS  Google Scholar 

  • Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC (1998) Novel antipsychotics and new onset diabetes. Biol Psychiatry 44: 778–783

    Article  PubMed  CAS  Google Scholar 

  • Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR (1999) Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60: 358–363

    Article  PubMed  CAS  Google Scholar 

  • World Health Organization (1998) Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation on Obesity. World Health Organization, Geneva, pp 5860

    Google Scholar 

  • Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425–432

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. F. Theisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Linden
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Sommerlad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J.-C. Krieg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Remschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Hebebrand
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik und Poliklinik, Univ.-Krankenhaus Eppendorf, Martinistraße 52, D-20246, Hamburg, Deutschland

    D. Naber

  2. Psychiatrische Universitätskliniken Basel, Wilhelm-Kleine-Straße 27, CH-4025, Basel, Switzerland

    F. Müller-Spahn

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Theisen, F., Linden, A., Sommerlad, C., Krieg, JC., Remschmidt, H., Hebebrand, J. (2001). Gewichtsveränderungen unter Neuroleptika: Epidemiologie, Regulationsmechanismen und klinische Aspekte. In: Naber, D., Müller-Spahn, F. (eds) Leponex. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59454-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59454-0_13

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-41135-2

  • Online ISBN: 978-3-642-59454-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation